An Open-label, Dose-finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Diagnosis of unresectable stage IIIB or IV non-small cell lung cancer (NSCLC)

- No more than one prior chemotherapy

- Adequate hematologic, renal and hepatic function

- Measurable disease or evaluable disease on CAT scan or MRI

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Able to fast for 10 hrs twice during the study - Able to tolerate oral medications

- Life expectancy of at least 3 months

Exclusion Criteria:

- Symptomatic or untreated central nervous system metastases requiring current
treatment

- History of arterial thrombosis within 1 year prior to enrollment

- Anticoagulant therapy, except for warfarin of less than 2mg per day

- Symptomatic peripheral neuropathy

- History of pulmonary hemorrhage or hemoptysis

- Myocardial infarction within 1 year before enrollment

- Uncontrolled hypertension [diastolic greater than 85 mmHg; systolic greater than 145
mmHg]

- History of other cancer, unless treated with no known active disease for longer than
3 years

- Previous treatment with AMG 706 or panitumumab, previous treatment with inhibitors of
VEGF or EGF

- No antibody treatment for 6 weeks prior to enrollment

- Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive